|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1993-4-28
|
|
pubmed:abstractText |
The bacteriologic and clinical efficacies of 3 days of lomefloxacin therapy were compared with those of 3 days of norfloxacin therapy for the treatment of acute uncomplicated urinary tract infections in a prospective, randomized, double-blind study. One hundred sixty-four subjects were enrolled at five Canadian centers; 84 received lomefloxacin, and 80 received norfloxacin. Escherichia coli (84%) and Staphylococcus saprophyticus (11%) were the most common organisms isolated. Forty subjects (24%) had low quantitative counts in their pretherapy urine specimens. In the intent-to-treat analysis, 76 lomefloxacin subjects (91%) and 76 norfloxacin subjects (95%) were cured or improved at follow-up 5 to 9 days posttreatment and 73 (87%) and 71 (89%) subjects from the lomefloxacin and norfloxacin groups, respectively, were cured or improved at 4 to 6 weeks posttreatment. Bacteriologic eradication occurred in 61 of 63 lomefloxacin subjects (97%) with > or = 10(8) CFU/liter in their pretherapy specimens and 56 of 59 norfloxacin subjects (95%) at 5 to 9 days and 55 (87%) and 53 (90%) subjects from the lomefloxacin and norfloxacin groups, respectively, at 4 to 6 weeks. There were no statistically significant differences in outcome. Adverse effects which were potentially related to the study medications were reported by 26% of the subjects who received lomefloxacin and 25% of the subjects who received norfloxacin. There were no severe adverse events, and only one subject discontinued therapy. These data suggest that 3 days of therapy with either lomefloxacin or norfloxacin is effective in the treatment of acute uncomplicated urinary tract infections.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/8384818-1316067,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8384818-1316074,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8384818-1316075,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8384818-1316077,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8384818-1599352,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8384818-1670063,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8384818-1929311,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8384818-1929343,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8384818-2012351,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8384818-2193352,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8384818-2672257,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8384818-3134843,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8384818-3257670,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8384818-3484773,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8384818-3551837,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8384818-3717940,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8384818-3896186,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8384818-6918057,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8384818-7099208
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0066-4804
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
37
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
574-9
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:8384818-Acute Disease,
pubmed-meshheading:8384818-Adolescent,
pubmed-meshheading:8384818-Adult,
pubmed-meshheading:8384818-Aged,
pubmed-meshheading:8384818-Anti-Infective Agents,
pubmed-meshheading:8384818-Canada,
pubmed-meshheading:8384818-Double-Blind Method,
pubmed-meshheading:8384818-Female,
pubmed-meshheading:8384818-Fluoroquinolones,
pubmed-meshheading:8384818-Humans,
pubmed-meshheading:8384818-Middle Aged,
pubmed-meshheading:8384818-Norfloxacin,
pubmed-meshheading:8384818-Prospective Studies,
pubmed-meshheading:8384818-Quinolones,
pubmed-meshheading:8384818-Treatment Outcome,
pubmed-meshheading:8384818-Urinary Tract Infections
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Treatment of acute uncomplicated urinary tract infections with 3 days of lomefloxacin compared with treatment with 3 days of norfloxacin.
|
|
pubmed:affiliation |
University of Manitoba, Winnipeg, Canada.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
